The paradox of pyrazinamide: An update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria

Journal of Communicable Diseases

Volumn 38, Issue 3, 2006, Pages 288-298

  Singh, Pushpendra ^a   Mishra, A K ^a   Malonia, S K ^a   Chauhan, D S ^a   Sharma, V D ^a   Venkatesan, K ^a   Katoch, V M ^a  

^a NATIONAL JALMA INSTITUTE FOR LEPROSY AND OTHER MYCOBACTERIAL DISEASES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDASE; PNCA PROTEIN, MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; MYCOBACTERIUM TUBERCULOSIS; REVIEW; TUBERCULOSIS;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; TUBERCULOSIS;

EID: 33846451407     PISSN: 00195138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. McKenzei D, Malone L, Kushner S et al. The effect of nicotinic acid amide on experimental tuberculosis of white mice. J Lab Clin Med 1948;33:1249-1253.
2. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 1978;53:5-12.
3. Trivedi SS and Desai SG. Pyrazinamidase activity of Mycobacterium tuberculosis- a test of sensitivity to pyrazinamide. Tubercle 1987;68:221-224.
4. McClatchy JK, Tsang AY and Cernich MS. Use of pyrazinamidase activity on Mycobacterium tuberculosis as a rapid method for determination pyrazinamide susceptibility. Antimicrob Agents Chemother 1981;20:556-557.
5. Butler WR and Kilburn JO. Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity. Antimicrob Agents Chemother 1983;24:600-601.
6. Salfinger M and Heifets LB. Determination of pyrazinamide MIC for Mycobacterium tuberculosis at different pH by radiometric assay. Antimicrob Agents Chemother 1988;32:1002-1004.
7. Heifets L, Flory MA and Lindholm Levy. Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis? Antimicrob Agents Chemother 1989;33:1252-1254.
8. Zhang Y, Scorpio A, Nikaido H et al. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 1999;181:2044-2049.
9. Boshoff HI and Mizrahi V. Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides. J Bacteriol 2000;182:5479-5485.
10. Blanchard JS. Molecular mechanism of drug resistance in Mycobacterium tuberculosis. Annu Rev Biochem 1996;65:215-239.
11. Rattan A, Kalia A and Ahmed N. Multidrug resistant Mycobacterium tuberculosis: Molecular perspective. Indian J Tub 1999;46:57-68.
12. Zimhony O, Cox JS, Welch JT et al. Pyrazinamide inhibits the eukaryotic like fatty acid synthase I (FAS-I) of Mycobacterium tuberculosis. Nat Med 2000;6:1043-1047.
13. rd. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J Bacteriol 2002;184:2167-2172.
14. Zhang Y and Mitchison DA. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003;7:6-21.
15. Konno K, Feldman FM and McDermott W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Resp Dis 1967;95:461- 469.
16. Sun Z and Zhang Y. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug, pyrazinamide. Antimicrob Agents Chemother 1999;43:537-542.
17. Konno K, Nagayama H and Oka S. Nicodinamidase in mycobacteria: a method for distinguishing bovine type tubercle bacilli from other mycobacteria. Nature 1959;184:1743-1744.
18. Wayne LG. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am Rev Resp Dis 1974;109:147-151.
19. Sreevatsan S, Pan X, Zhang Y et al. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 1997;41:636-640.
20. Scorpio A, Collins D Whipple D et al. Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in bovine pyrazinamidase gene. J Clin Microbiol 1997;35:106-110.
21. Raynaud C, Laneelle MA, Senaratne RH et al. Mechanism of PZA resistance in mycobacteria: Importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiology 1999;145:1359-1367.
22. Scorpio A and Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug, pyrazinamide in tubercle bacillus. Nat Med 1996;2:662-667.
23. Miller MA, Thibert L, Desjardins F et al. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: Comparision of BACTEC method with Pyrazinamidase assay. J Clin Microbiol 1995;33:2468-2470.
24. Marttila HJ, Marjamaki M, Vyshnevskaya E et al. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob Agents Chemother 1999;43:1764- 1766.
25. Mestdagh M, Fonteyne PA, Realini L et al. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999;43:2317-2319.
26. Hirano K, Takahashi M, Kazumi Y et al. Mutation in pncA is a major mechanism of pyrazinamide resiatance in Mycobacterium tuberculosis. Tuberc Lung Dis 1998;78:117-122.
27. Lemaitre N, Sougakoff W, Truffot-Pernot C et al. Characterization of new mutations in pyrazinamide resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of pyrazinamidase pncA. Antimicrob Agents Chemother 1999;43:1761- 1763.
28. Cheng-Shao JI, Thibert L, Snachez T et al. pncA mutations as major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis spread of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother 2000;44:528-532.
29. Hou LD, Osei-Hyiaman, Zhang Z et al. Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. Epidemiol Infect 2000;124:227-232.
30. Bishop KS, Blumberg L, Trollip AP et al. Characterization of the pncA gene in M. tuberculosis isolates from Gauteng, South Africa. Int J Tuberc Lung Dis 2001;5:952-957.
31. Huang T-S, Lee SS-J, Tu H-Z et al. Correlarion between Pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. J Antimicrob Agents Chemother 2003;47:3672-3673.
32. Miyagi C, Yamane N, Yogesh B et al. Genetic and phenotypic characterization of pyrazinamide resistant Mycobacterium tuberculosis complex isolates in Japan. Diagn Microbiol Infect Dis 2004;48:111-116
33. Traceska T, Janssone I, Baaumanis V et al. Spectrum of pncA mutations in multi-drug resistant Mycobacterium tuberculosis isolates obtained in Latvia. Antimicrob Agents Chemother 2004;48:3209-3210.
34. Portugal I, Barreiro L, Moniz-Pereira J et al. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. Antimicrob Agents Chemother. 2004;48:2736-2738.
35. Rodrigues VDFS, Telles MA, Ribeiro MO et al. Characterization of pncA mutations in pyrazinamide resistant Mycobacterium tuberculosis in Brazil. Antimicrob Agents Chemother 2005;49:444-446.
36. Mizrahi V and Andersen J. DNA repair in Mycobacterium tuberculosis. what have we learn from the genome sequence. Mol Microbiol 1998;29:1331-1339.
37. Hewlett D Jr, Horn DL and Alfaalla C. Drug resistant tuberculosis inconsistent result of pyrazinamide susceptibility testing. JAMA 1995;273:916-917.
38. Mestdagh M, Realini L, Fonteyne PA et al. Correlation of pncA sequence with Pyrazinamide resistance level in BACTEC for 21 Mycobacterium tuberculosis clinical isolates. Microb Drug Resist 2000;6:283-287.
39. Wade MM, Volokhov D, Peredelchuk M et al. Accurate mapping of mutations of pyrazinamide resistant Mycobacterium tuberculosis strains with a scanning frame oligonucleotide microarray. Diagn Microbiol Infect Dis 2004;49:89-97.